Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.

Acute Disease Adolescent Adult Allografts CD4-CD8 Ratio CD4-Positive T-Lymphocytes CD8-Positive T-Lymphocytes Disease-Free Survival Female Graft vs Host Disease / blood HLA Antigens Humans Leukemia / blood Male Middle Aged Myelodysplastic Syndromes / blood Peripheral Blood Stem Cell Transplantation Recurrence Survival Rate
Allogeneic GVHD dose T cell Transplantation

Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
09 2019
Historique:
received: 11 03 2019
revised: 02 05 2019
accepted: 03 05 2019
pubmed: 16 5 2019
medline: 30 7 2020
entrez: 16 5 2019
Statut: ppublish

Résumé

Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). We excluded ex vivo and in vivo T cell-depleted transplantations. Correlative analysis was performed between CD3

Identifiants

DOI: 10.1016/j.bbmt.2019.05.007 PMID: 31085303 PMC: PMC7071947
pubmed: 31085303
pii: S1083-8791(19)30291-5
doi: 10.1016/j.bbmt.2019.05.007
pmc: PMC7071947
mid: NIHMS1551555
pii:
doi:

Substances chimiques

HLA Antigens 0

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1875-1883

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145231
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA188523
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

Blood. 2011 Mar 24;117(12):3268-76
pubmed: 21245483
Blood. 2012 Jan 5;119(1):296-307
pubmed: 22010102
Blood. 2001 Jan 15;97(2):383-7
pubmed: 11154212
Blood. 2016 Aug 18;128(7):1013-7
pubmed: 27385791
J Clin Oncol. 2012 Nov 20;30(33):4084-90
pubmed: 23045576
Cancer Treat Rev. 2010 Nov;36(7):528-38
pubmed: 20381970
Leukemia. 2003 May;17(5):869-75
pubmed: 12750699
Biol Blood Marrow Transplant. 2012 Jun;18(6):887-93
pubmed: 22062803
J Clin Oncol. 2012 Sep 10;30(26):3194-201
pubmed: 22869882
Oncotarget. 2016 May 10;7(19):27255-66
pubmed: 27036034
Leukemia. 2003 May;17(5):856-8
pubmed: 12750697
Blood. 2001 Dec 1;98(12):3221-7
pubmed: 11719357
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
J Clin Oncol. 2017 Dec 20;35(36):4003-4011
pubmed: 29040031
Comput Methods Programs Biomed. 2011 Jan;101(1):87-93
pubmed: 20724020
Biol Blood Marrow Transplant. 2018 Apr;24(4):708-716
pubmed: 29196077
Biol Blood Marrow Transplant. 2014 Sep;20(9):1418-25
pubmed: 24892261
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
J Clin Invest. 2015 Jul 1;125(7):2677-89
pubmed: 26053664
Blood. 2016 Feb 4;127(5):646-57
pubmed: 26670634
J Clin Oncol. 2013 Apr 20;31(12):1530-8
pubmed: 23478054
Blood. 2011 Jun 16;117(24):6714-20
pubmed: 21493797
Br J Haematol. 2001 Oct;115(1):95-104
pubmed: 11722418
Clin Cancer Res. 2015 May 1;21(9):2020-8
pubmed: 25348512
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Blood. 2012 May 17;119(20):4786-97
pubmed: 22408260
N Engl J Med. 2012 Oct 18;367(16):1487-96
pubmed: 23075175
Blood. 1995 Sep 1;86(5):2041-50
pubmed: 7655033
Lifetime Data Anal. 1995;1(2):145-56; discussion 157-9
pubmed: 9385097
J Clin Oncol. 2015 Jul 20;33(21):2392-8
pubmed: 26056179
Blood. 2011 Jun 23;117(25):6963-70
pubmed: 21464372
J Clin Oncol. 2014 Aug 1;32(22):2365-72
pubmed: 24982459
J Clin Oncol. 2008 Dec 10;26(35):5728-34
pubmed: 18981462
N Engl J Med. 2001 Jan 18;344(3):175-81
pubmed: 11172139
Comput Methods Programs Biomed. 2007 Nov;88(2):95-101
pubmed: 17850917
Bone Marrow Transplant. 2019 May;54(5):775-781
pubmed: 30375493
Blood. 2016 Mar 17;127(11):1502-8
pubmed: 26764356
Blood. 1990 Feb 1;75(3):555-62
pubmed: 2297567
Bone Marrow Transplant. 2018 Dec;53(12):1522-1531
pubmed: 29703966
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269

Auteurs

Ayman Saad (A)

Division of Hematology, The Ohio State University, Columbus, Ohio.

Lawrence Lamb (L)

University of Alabama at Birmingham, Birmingham, Alabama.

Tao Wang (T)

Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Michael T Hemmer (MT)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Stephen Spellman (S)

Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be the Match, Minneapolis, Minnesota.

Daniel Couriel (D)

Utah Blood and Marrow Transplant Program, Salt Lake City, Utah.

Amin Alousi (A)

Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Joseph Pidala (J)

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida.

Hisham Abdel-Azim (H)

Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.

Vaibhav Agrawal (V)

Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.

Mahmoud Aljurf (M)

Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Amer M Beitinjaneh (AM)

University of Miami, Miami, Florida.

Vijaya Raj Bhatt (VR)

The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.

David Buchbinder (D)

Division of Pediatric Hematology, Children's Hospital of Orange County, Orange, California.

Michael Byrne (M)

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.

Jean-Yves Cahn (JY)

Department of Hematology, CHU Grenoble Alpes, Grenoble, France.

Mitchell Cairo (M)

Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, New York, New York.

Paul Castillo (P)

UF Health Shands Children's Hospital, Gainesville, Florida.

Saurabh Chhabra (S)

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Miguel Angel Diaz (MA)

Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.

Shatha Farhan (S)

Henry Ford Hospital Bone Marrow Transplant Program, Detroit, Michigan.

Yngvar Floisand (Y)

The National Hospital, Oslo, Denmark.

Hadar A Frangoul (HA)

Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, Tennessee.

Shahinaz M Gadalla (SM)

Division of Cancer Epidemiology & Genetics, Clinical Genetics Branch, National Cancer Institute, Rockville, Maryland.

James Gajewski (J)

Consultant at Lu Daopei Hospital, Beijing, China.

Robert Peter Gale (RP)

Hematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.

Manish Gandhi (M)

Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota.

Usama Gergis (U)

Hematologic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.

Betty Ky Hamilton (BK)

Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

Peiman Hematti (P)

Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Gerhard C Hildebrandt (GC)

Markey Cancer Center, University of Kentucky, Lexington, Kentucky.

Rammurti T Kamble (RT)

Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.

Abraham S Kanate (AS)

Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia.

Pooja Khandelwal (P)

Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Aleksandr Lazaryan (A)

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida.

Margaret MacMillan (M)

University of Minnesota Blood and Marrow Transplant Program, Pediatrics, Minneapolis, Minnesota.

David I Marks (DI)

Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.

Rodrigo Martino (R)

Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Parinda A Mehta (PA)

Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Taiga Nishihori (T)

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, Florida.

Richard F Olsson (RF)

Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.

Sagar S Patel (SS)

Blood and Marrow Transplant Program, Cleveland Clinic Foundation, Cleveland, Ohio.

Muna Qayed (M)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.

Hemalatha G Rangarajan (HG)

Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Nationwide Children's Hospital, Columbus, Ohio.

Ran Reshef (R)

Blood and Marrow Transplantation Program and Columbia Center for Translational Immunobiology, Columbia University Medical Center, New York, New York.

Olle Ringden (O)

Translational Cell Therapy Research, Karolinska Institute, Stockholm, Sweden.

Bipin N Savani (BN)

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.

Harry C Schouten (HC)

Department of Hematology, Academische Ziekenhuis, Maastricht, Netherlands.

Kirk R Schultz (KR)

Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, Britich Columbia, Canada.

Sachiko Seo (S)

Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.

Brian C Shaffer (BC)

Memorial Sloan Kettering Cancer Center, New York, New York.

Melhem Solh (M)

The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia.

Takanori Teshima (T)

Hokkaido University Hospital, Sapporo, Japan.

Alvaro Urbano-Ispizua (A)

Department of Hematology, Hospital Clinic, University of Barcelona, IDIBAPS, and Josep Carreras Institute of Research, Barcelona, Spain.

Leo F Verdonck (LF)

Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.

Ravi Vij (R)

Division of Hematology and Oncology, Washington University School of Medicine, St Louis, Missouri.

Edmund K Waller (EK)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Basem William (B)

Division of Hematology, The Ohio State University, Columbus, Ohio.

Baldeep Wirk (B)

Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.

Jean A Yared (JA)

Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.

Lolie C Yu (LC)

Division of Hematology/Oncology and HSCT, Center for Cancer and Blood Disorders, Children's Hospital/Louisiana State University Medical Center, New Orleans, Louisiana.

Mukta Arora (M)

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota. Electronic address: arora005@umn.edu.

Shahrukh Hashmi (S)

Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie aigüe › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Régions du corps › Transplants › Allogreffes › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Phénomènes du système immunitaire › Rapport CD4-CD8 › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes HLA › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Maladies de la moelle osseuse › Syndromes myélodysplasiques › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Transplantation de cellules souches de sang périphérique › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › Impact of T Cell Dose on Outcome of T...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Impact of T Cell Dose on Outcome of T...